Stemline Therapeutics — IPO Roadshow (May 2013)
33 slides from Stemline Therapeutics's IPO roadshow presentation, May 7, 2013
Slide 1: Stemline Therapeutics Corporate Presentation May 2013
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-188378 May 6, 2013 Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation May 2013
Slide 2: Forward-looking statements
2 This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,”
Slide 3: Offering and prospectus notice
3 This presentation highlights basic information about us and the offering. Because it is a summary, it does not contain all of the information that you should consider before investing. We have filed a registration statement (including a prospectus) with the SEC for the offering to which this prese
Slide 4: Biopharmaceutical company targeting Cancer Stem Cells
Biopharmaceutical company targeting Cancer Stem Cells (CSCs) with near-term registrational opportunities SL-401 and SL-701 have demonstrated multiple durable complete responses (CRs) and survival advantage in advanced hematologic and brain cancers, respectively SL-401 entering pivotal programs in or
Slide 5: Management and Board of Directors
Ivan Bergstein, M.D. – Chief Executive Officer Founded Stemline and advanced Company from concept to current clinical stage Pioneer in the therapeutic targeting of Cancer Stem Cells; filed early patents Former Medical Director of Access Oncology, Inc.; company subsequently acquired Eric Rowinsky, M.
Slide 6: Dual targeting of Cancer Stem Cells and Tumor Bulk
Dual targeting of both Cancer Stem Cells (CSCs) and Tumor Bulk with a Single Agent 6 Tumor relapse CSCs survive Tumor bulk killed CSCs regrow tumor CSCs and tumor bulk killed Tumor bulk Cancer stem cell (CSC) Tumor Standard therapy Stemline therapy Cancer destroyed Our Novel Approach Identification
Slide 7: Pipeline
Therapy Indication Preclinical Phase 1/2 Phase 2b SL-401 BPDCN Relapsed or refractory Other rare IL-3R+ cancers* Relapsed or refractory AML Relapsed or refractory Multiple myeloma Relapsed or refractory High risk MDS Relapsed or refractory SL-701 Pediatric malignant glioma Newly diagnosed Adult high
Slide 8: SL-401 Program
Stemline SL-401 Program
Slide 9: SL-401 targeted therapy directed to IL-3 receptor
Novel targeted therapy directed to interleukin-3 receptor (IL-3R) IL-3R is overexpressed on most heme cancers AML, BPDCN, myeloma, MDS, hairy cell leukemia, mastocytosis, basophilic leukemias, CML, Hodgkin’s and Non-Hodgkin’s lymphoma, others Single agent clinical activity to date in multiple indica
Slide 10: SL-401 mechanism of action
IL-3 10 Cancer Stem Cell Payload Tumor Bulk Cell SL-401 Normal Cell SL-401 is a recombinant protein consisting of human IL-3 linked to truncated diphtheria toxin payload SL-401 kills malignant cells SL-401 delivers payload to IL-3R+ malignant cells Intracellular release of cytotoxic payload Inhibiti
Slide 11: IL-3R is overexpressed on AML
11 IL-3R is overexpressed on AML relative to normal bone marrow IL-3R is overexpressed on AML CSCs and not present on normal stem cells IL-3R Counts <1% normal hematopoietic stem cells express IL-3R Normal Bone Marrow Limited IL-3R expression AML Diffuse IL-3R expression IL-3R Counts >99% of AML CSC
Slide 12: AML and BPDCN treatment landscape and patient populations
AML Treatment BPDCN Treatment 1st Line Chemotherapy (Ara-C + anthracycline) approved Bone marrow transplantation when indicated No approved treatment No standard of care 2nd Line No approved treatment Standard of care: additional chemotherapy No approved treatment No standard of care 3rd Line No app
Slide 13: Multi-center Phase 1/2 trial summary
Multi-center Phase 1/2 trial Advanced hematologic cancer patients (n=82) Single agent activity with only a single cycle in multiple indications (AML, BPDCN, MDS) Durable complete responses in AML and BPDCN Survival benefit in heavily pretreated AML Well-tolerated Most common side effects: reversible
Slide 14: Blast reductions and disease stabilization after single cycle
14 High rates of blast reductions and disease stabilization, after only a single cycle of therapy BPDCN (n=5) AML Relapsed, refractory (n=59) AML >3rd line (n=35*) AML Not chemo candidate (n=11) MDS Refractory, High risk (n=7) Tumor shrinkages/ disease stabilization 80% 46% 43% 55% 43% Tumor shrinka
Slide 15: BPDCN is an unmet medical need
15 BPDCN is an unmet medical need Uncommon & highly aggressive hematologic malignancy Previous names: Blastic NK cell lymphoma; Agranular CD4+/CD56+ hematodermic neoplasm Involves skin, bone marrow, blood, lymph nodes, spleen; often terminal leukemic phase Poor prognosis, no standard of care, tradit
Slide 16: 80% overall response rate in BPDCN
80% overall response rate; single cycle of SL-401 induced responses in 4 of 5 relapsed/refractory BPDCN patients (3 CRs, 1 PR) 2 CRs of >3 month duration 3rd line BPDCN patient Blasts in marrow, low blood counts, enlarged lymph nodes & spleen Resolution after SL-401 single cycle, CR 5 months 4th lin
Slide 17: Patient community excerpts
Excerpts from http://community.lls.org/thread/2436 CR pt #1 CR pt #2 17
Slide 18: Complete responses in AML patients
18 (+) Blasts Recovering marrow Normal hematopoiesis Pre-SL-401 2 weeks post-SL-401 4 weeks post-SL-401 CR #1 (8 mos. duration): Patient had failed standard 1st line therapy (Ara-C + daunorubicin) CR #2 (>25 mos. duration): 4th line AML patient who failed 2 prior bone marrow transplants Absolute neu
Slide 19: Decrease in CSC activity in treated patients
19 Decrease in CSC activity in SL-401 treated patients (n=3) First clinical demonstration that a CSC-directed compound can decrease CSC activity in patients Pre-SL-401 Day 15 Post-SL-401 Day 30 Post-SL-401 % Colonies (CSC assay) Mean CSC activity decreases over time in Patients treated with SL-401
Slide 20: Longer overall survival in AML patients
20 Longer overall survival in AML patients (>3rd line) treated with only a single cycle of SL-401 compared with historical data Overall Survival (%) SL-401 treated patients Median OS = 5.6 months (95% CI: 2.5, 10.8 months) Historical OS 1.5 months Months >2x the median OS vs. historical data (all do
Slide 21: SL-701 Program
Stemline SL-701 Program
Slide 22: Novel brain cancer vaccine SL-701
Novel brain cancer vaccine consisting of synthetic peptides SL-701 targets, IL-13Rα2 and Ephrin-A2 (EphA2), are overexpressed on brain CSCs and tumor bulk Single agent activity in Phase 1/2 trials in advanced adult and pediatric brain cancers Durable complete responses and multiple partial responses
Slide 23: SL-701 responses in pediatric and adult glioma
SL-701 induced a PR (15 mo) in a child with radiation-resistant brainstem glioma 5 mo. post-SL-701 Baseline Partial response SL-701 induced a CR (>23 mos in an adult with GBM refractory to 1st line therapy Baseline Complete response Pre-SL-701 33 wks post-SL-701 Pre-SL-701 Adult High-Grade Glioma (r
Slide 24: Post-SL-701 brain biopsy
25 Reactive gliosis Numerous CD68+ macrophages Abundant CD8+ T cells Post-SL-701 brain biopsy demonstrates inflammation, including CD8+ T cells, indicative of an SL-701-induced immune response against the brain tumor in this patient Pre-SL-701 (baseline) Nine weeks post-SL-701 treatment shows tumor
Slide 25: Planned SL-701 Phase 2b trials
Pediatric non-brainstem and brainstem glioma Phase 2b trial in U.S. to be led by St. Jude’s Children’s Research Hospital and the Pediatric Brain Tumor Consortium under NCI funding Phase 2b trial in Europe (planned) Adult second-line GBM Phase 2b trial: SL-701 + Avastin® 26
Slide 26: StemScreen Platform, Preclinical Pipeline, and Intellectual Property
Stemline StemScreen® Platform, Preclinical Pipeline, and Intellectual Property
Slide 27: StemScreen platform and preclinical pipeline
28 Proprietary high throughput screen identifies novel compounds that target CSCs Based on landmark discovery that cancer cell lines harbor CSCs Technology identifies CSCs in cell lines and permits high throughput screening of compound libraries CSCs (fluorescent reporter) Compound library StemScree
Slide 28: Leading intellectual property estate
Leading intellectual property estate Broad and early filings in CSC space 13 issued patents, 30 pending Therapeutics directed to CSCs Broad mAb-based therapies targeting CSCs Specific mAb-based therapies to important oncology targets In combination with companion diagnostics CSC-directed diagnostics
Slide 29: Financial Summary
Stemline Financial Summary Stemine
Slide 30: Financial Summary
Financial Summary (1) Pro forma as adjusted for IPO, offering price at $10.00 per share, 3.8M shares offered with over-allotment. Pro Forma as of December 31, 20121 Cash and cash equivalents ($M) 33.4 Total assets ($M) 36.4 Shares Outstanding (M) 7.5 31
Slide 31: Milestones
Stemline Milestones
Slide 32: Milestones
33 □ Present SL-401 data (BPDCN, AML, et al) at ASCO (2013) □ Present SL-401 data (BPDCN, et al) at ASH (2013) □ SL-401 pivotal program in BPDCN (2014-15) □ SL-401 Phase 2 trial in other rare IL-3R+ diseases (2014-15) □ SL-401 pivotal randomized Phase 2b trial in 3rd-line AML (2014-16) □ SL-401 Phas
Slide 33: Stemline Therapeutics, Inc.
Stemiine Stemline Therapeutics, Inc. NASDAQ: STML Corporate Presentation May 2013